CCR5 and neoplasm: CCR5, a major CCL5 receptor, was targeted in several studies by maraviroc, leading to controversial results in terms of tumor cell proliferation (48–51), which possibly reflect the use of different model systems and/or the ability of CCL5 to activate CCR1 and CCR3 in addition to CCR5.